

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/20138> holds various files of this Leiden University dissertation.

**Author:** Vrouwe, Mischa G.

**Title:** DNA damage responses in mammalian cells : focus on signaling and repair

**Date:** 2012-11-20

# 5

## **Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells.**

Alex Pines, Christian D. Kelstrup, Mischa G. Vrouwe<sup>‡</sup>, Jordi C. Puigvert<sup>‡</sup>,  
Dimitris Typas<sup>‡</sup>, Branislav Misovic, Anton de Groot, Louise von Stechow,  
Bob van de Water, Erik H.J. Danen, Harry Vrieling<sup>\*</sup>, Leon H.F. Mullenders<sup>\*</sup>,  
and Jesper V. Olsen<sup>2\*</sup>

<sup>‡</sup>,<sup>\*</sup> These authors contributed equally to this work

Molecular and Cellular Biology. Dec 31; 24:4964-77. 2011

## ABSTRACT

Cellular responses to DNA damaging agents involve the activation of various DNA damage signaling and transduction pathways. Using quantitative and high-resolution tandem mass spectrometry we determined global changes in protein level and phosphorylation site profiles following treatment of SILAC labeled murine embryonic stem cells with the anticancer drug cisplatin. Network and pathway analyses indicated that processes related to the DNA damage response and cytoskeleton organization were significantly affected. Although the ATM and ATR consensus sequence [S/T-Q motif] was significantly over-represented among hyper-phosphorylated peptides, about half of the more than 2-fold up-regulated phosphorylation sites based on consensus sequence were not direct substrates of ATM and ATR. Eleven protein kinases mainly belonging to the MAPK family were identified to be regulated in their kinase domain activation loop. The biological importance of three of these kinases [CDK7, PIK1, and KPCD1] in the protection against cisplatin-induced cytotoxicity was demonstrated by siRNA mediated knockdown. Our results indicate that the cellular response to cisplatin involves a variety of kinases and phosphatases acting not only in the nucleus, but also regulating cytoplasmic targets resulting in extensive cytoskeletal rearrangements. Integration of transcriptomic and proteomic data revealed a poor correlation between changes in the relative level of transcripts and their corresponding proteins, but a large overlap in affected pathways at the level of mRNA, protein and phosphoprotein. This study provides an integrated view on pathways activated by genotoxic stress and deciphers kinases that play a pivotal role in regulating cellular processes other than the DNA damage response.

## INTRODUCTION

Cancer chemotherapy drugs are designed to selectively kill cells that divide rapidly, being a main feature of most cancer cells. Cisplatin [cis-diamminedichloroplatinum (II) (CDDP)] is among the most widely employed drugs in chemotherapy administered as curative treatment of several forms of cancer including ovarian, cervical, head and neck, esophagus, non-small-cell lung, and especially testicular cancer [Loehrer and Einhorn, 1984; Keys et al., 1999; Morris et al., 1999]. Cisplatin binds to DNA and forms a spectrum of intra- and inter-strand DNA cross-links as well as mono adducts. These DNA adducts are thought to mediate their cytotoxic effects by interfering with transcription and replication, ultimately leading to the induction of apoptosis [Todd and Lippard, 2009]. Cisplatin adducts distort the DNA duplex resulting in the exposure of the DNA minor groove to which several classes of proteins can bind, including high-mobility group (HMG) proteins and transcription factors that contribute to cisplatin induced toxicity [Wang and Lippard, 2005].

Repair of cisplatin-DNA adducts involves proteins from multiple DNA repair pathways, i.e., nucleotide excision repair (NER), homologous recombination, post-replication repair, and mismatch repair (MMR) [Wang and Lippard, 2005; Dronkert and Kanaar, 2001]. NER is the major pathway responsible for the removal of cisplatin-DNA adducts *in vitro* and *in vivo* [Wang et al., 2003; Furuta et al., 2002] and hence, the marked sensitivity of testicular cancer to cisplatin has been correlated with low levels of NER proteins, i.e. XPA and ERCC1-XPF [Welsh et al., 2004]. DNA damage caused by cisplatin activates several signal transduction pathways including MAPK, AKT, c-ABL, and ATM/ATR/DNA-PK dependent pathways regulating a variety of processes such as drug uptake, DNA damage signaling, cell cycle arrest, DNA repair, and cell death [Wang and Lippard, 2005].

Treatment of patients with cisplatin is compromised by the substantial risk of severe toxicity, i.e. anemia, nausea, and neurotoxicity [McWhinney et al., 2009]. Tumors frequently become resistant to the drug [Oliver et al., 2010; Borst et al., 2008] and multiple resistance mechanisms have been identified, including an increased cellular efflux or a decreased cellular import of cisplatin [Safaei and Howell, 2005; Hall et al., 2008]. Cisplatin resistance can also occur through enhanced DNA damage repair or increased tolerance to DNA damage [Borst et al., 2008].

Improvement of cancer therapy mediated by chemotherapeutic drug agents such as cisplatin requires better understanding of the cellular pathways underlying toxicity and drug resistance. Indeed, most of the recent advances in cancer treatment are based on drastic improvements in conceptual understanding of cellular networks. Cellular responses to DNA damage such as cisplatin-induced intra- and inter-strand DNA cross-links are controlled by a global signaling network called the DNA damage response (DDR) [Jackson and Bartek, 2009] and mediated by post-translational protein modifications [Choudhary and Mann, 2010]. One of the most frequent modifications is the reversible and dynamic phosphorylation of proteins at specific serine, threonine, and tyrosine residues that control the activity of the majority of cellular processes. It has been estimated that almost 70% of all proteins in mammalian cells are phosphorylated at some point during their expression [Olsen et al., 2010]. Key signalling molecules in DDR are the protein kinases

ATM [ataxia telangiectasia mutated] and ATR [ATM and Rad3-related] [Bartek and Lukas, 2007]. Matsuoka and coworkers recently identified over 900 phosphorylation sites in about 700 proteins by phosphoproteome analysis of protein targeted by the ATM and ATR kinases after exposure to ionizing radiation [Matsuoka et al., 2007], however knowledge of the genome wide protein phosphorylation response to genotoxic insults is still limited. This study aimed to identify the molecular processes and cellular pathways that are affected after treatment with cisplatin one of the most commonly used chemotherapeutic drugs. To achieve these goals, we examined the cisplatin induced stress responses, changes in proteins level and global phosphorylation site profiles by quantitative phosphoproteomics. Besides activation of the DDR kinases ATM and ATR, we identified 11 other protein kinases with altered activities in response to cisplatin. We applied siRNA mediated knockdown to demonstrate that 3 kinases have important protective roles in the cellular response to cisplatin induced toxicity. Our dataset identified the cytoskeleton as a novel target of the cisplatin induced stress response. In addition, integration of transcriptome, proteome and phosphoproteome data disclosed a strong correlation in affected pathways at the levels of transcription and protein phosphorylation.

## RESULTS

### Cisplatin-induced stress responses

Murine embryonic stem (mES) cells were selected as the cellular model for this study since they have the unique combination of a virtually infinite lifespan with uncompromised DDR. mES cells manage to maintain their genomic integrity through robust defense mechanisms against DNA damage, including effective DNA repair and a hypersensitive apoptotic response [Tichy and Stambrook, 2008]. These characteristics make mES suitable to study the molecular events that underlie the cellular responses related to cisplatin induced toxicity. To assess the kinetics of the cisplatin-induced stress response, we examined cell cycle progression, mitotic index and DNA strand breaks [by staining for  $\gamma$ H2AX] in cisplatin exposed mES cells over time. Cell cycle analysis following DNA synthesis labeling by EdU showed that, in the absence of cisplatin, about 65% of the ES cells were in S phase [G1 ~15% and G2/M ~20%, supplementary figure 1A]. After addition of cisplatin, we observed a time dependent inhibition of DNA synthesis: the incorporation of EdU was evident at 30 minutes, decreased after 2 hours, and was completely absent at 4 and 8 hours [figure 1A]. Inhibition of DNA replication and transcription has been widely considered to be a key to the mechanism of cisplatin cytotoxicity [Todd and Lippard, 2009]. No significant induction of apoptosis [estimated from the subG1 content] occurred during the treatment period [figure 1B] in agreement with previous results [Kruse et al., 2007]. In the absence of cisplatin, about 5% of the cells were in mitosis as estimated by FACS analysis of serine 10 phosphorylation of histone H3; nocodazole treated cells arrested in G2 or M-phase were used as positive control [supplementary figure 1B]. The maximal reduction in mitotic index was observed after 4 hours of cisplatin treatment and persisted through 8 hours [figure 1C]. Cisplatin mediated DNA damage signaling manifested by  $\gamma$ H2AX phosphorylation increased


with time, reaching its maximal level at 4 hours post-treatment as evidenced by western blot and MS analysis (figure 1D). Together, these time course experiments indicated a complete inhibition of DNA synthesis, a significant reduction of mitotic index, and a strong induction of DNA damage signaling after 4 hours of cisplatin treatment.

### Phosphoproteome analysis after cisplatin exposure

Stable isotope labeling by amino acids in cell culture technology (SILAC) [Ong et al., 2002] was applied to quantitatively and qualitatively analyze genome-wide protein phosphorylation events following exposure to cisplatin. mES were grown in media containing 'light' (control cells) or 'heavy' (treated cells) labeled forms of the amino acids arginine and lysine. Cells were exposed to 5  $\mu\text{M}$  cisplatin for 4 hours, mixed with untreated cells, lysed and subsequently digested with trypsin. The 4 hours time point was selected based on the kinetics of cisplatin-induced stress responses [see figure 1]. Phosphopeptides were selectively enriched by means of a two-step phosphopeptide enrichment procedure, i.e., SCX [strong cation exchange] chromatography followed by  $\text{TiO}_2$  column separation and subjected to online nanoflow liquid chromatography tandem mass spectrometry (nano-LC-MS/MS) analysis [Macek et al., 2009]. A total of 14 fractions were collected from SCX chromatography and after  $\text{TiO}_2$  enrichment, each fraction was analyzed by high-resolution tandem mass spectrometry on an LTQ-Orbitrap Velos MS [Olsen et al., 2009] using Higher-energy Collisional Dissociation (HCD) [Olsen et al., 2007] for all MS/MS events (figure 1E). The tandem mass spectra were identified by Mascot [www.matrixscience.com] and SILAC phosphopeptide pairs were quantified using the MaxQuant software suite [Cox et al., 2009] and the final dataset showed 11,034 unique phosphopeptides [false discovery rate (FDR) of < 1%] originating from 3,395 proteins [supplementary table 1]. Most phosphopeptides contained only a single phosphorylation site (figure 1F), but multiple phosphorylation sites were detected as well. Serine, threonine, and tyrosine phosphorylation sites comprised ~86.7%, ~13%, and ~0.3%, respectively (figure 1G).

The quantified phosphorylation site dataset revealed that approximately 4% of the phosphopeptides underwent a more than two-fold change in phosphorylation level after exposure to cisplatin, corresponding to 183 and 194 up- and down-regulated phosphopeptides, respectively. 324 phosphorylation sites were 1.5-2 fold up-regulated, while 725 phosphorylation sites were found to be 1.5-2 fold down-regulated (figure 2A and supplementary table 1). Many of the top 50 up-regulated phosphopeptides stemmed from proteins that are known to play key roles in DNA repair, chromatin remodeling, cell-cycle checkpoints (G1/S and G2/M) and transcription (figure 2B). Typically, multiple individual phosphorylation sites were identified for each protein but, interestingly, 44 proteins (most of them related to DNA repair) were found to contain both up-regulated phosphorylation sites and down-regulated [dephosphorylated] sites [supplementary figure 2].

To examine general validity of our findings we performed an independent experiment in the same ES cell line employing an identical concentration of cisplatin and exposure time (4hrs), as well as identical protocols to purify phosphopeptides [supplementary figure 6A]. The final dataset showed 11,966 unique phosphopeptides [supplementary table 6]. The quantified phosphorylation site dataset revealed that 224 and 706 up- and



**Figure 1.** [A] mES cells were treated with 5  $\mu$ M cisplatin for different times (as indicated) followed by EdU labeling for 45 minutes. Flow cytometric analysis evidenced a time-dependent inhibition of DNA synthesis. [B] mES cells were treated with 5  $\mu$ M cisplatin and the subG1 cell content was determined by flow cytometric analysis at different time points (as indicated). [C] Mitotic index of mES cells treated with 5  $\mu$ M cisplatin was determined at different time points (as indicated) by flow cytometric analysis [D] mES cells were treated with 5  $\mu$ M cisplatin and analyzed 0.5, 2, 4 and 8 hours later with indicated antibodies. [-] untreated sample. SILAC mass spectrometry spectrum of  $\gamma$ -H2AX phosphopeptide and unmodified H2A peptide. [E] Number of phosphopeptides [black bars] and unmodified peptides [grey bars] identified by MS analysis. [F] Number of peptides containing 0, 1, 2, 3, and 4 phosphorylation sites. [G] Phosphorylation site distribution over serine, threonine, and tyrosine residues.


down-regulated phosphopeptides respectively, underwent more than two-fold change in phosphorylation level after exposure to cisplatin [supplementary figure 6C].

### Cellular network analysis

Network and pathway analysis using MetaCore software indicated that processes related to DDR, i.e. cell cycle control, checkpoint activation, as well as apoptosis, were significantly overrepresented among proteins containing up-regulated phosphorylation sites (>1.5-fold and >2 fold) [figure 2C-E and supplementary figure 3]. The central signal transducers in the early cellular response to cisplatin are the protein kinases ATM and ATR [figure 3A-B]. On the other hand, the analysis of proteins containing down-regulated phosphorylation sites identified cytoskeleton and mitotic processes (>1.5-fold and >2 fold). Anaphase-promoting complex [APC], cell adhesion, Rho GTPases [RAC1, Cdc42], and mitosis initiation pathways were found significantly affected [figure 2D-F and supplementary figure 3]. Together, the strong inhibition of replicative DNA synthesis, the formation of DNA strand breaks and the reduction of mitotic index fit well with the activation of DDR [i.e., cell cycle checkpoints, DNA repair, and apoptosis] and inactivation of processes related to mitosis. Analysis of phosphorylation levels revealed the same processes significantly affected by cisplatin, when thresholds were set at 1.5 or 2.0 fold changes. This finding indicates that fold changes of 1.5 of phospho-protein level is relevant threshold to identify proteins and processes related to the genotoxic stress induced by cisplatin.

### Activation of ATM and ATR in response to cisplatin

In line with recent investigations [Matsuoka et al., 2007; Bennetzen et al., 2010; Stokes et al., 2007; Bensimon et al., 2010], we found that DNA damaging agents such as cisplatin provoke activation of ATM and ATR kinases as the substrate consensus sequence [SQ-TQ motif] of these kinases was significantly overrepresented (84 out of 183 peptide count) among the more than two-fold up-regulated phosphorylation sites [figure 3A]. Interestingly, whereas the phosphorylation of S<sup>1987</sup>, the important SQ motif in murine ATM required for its activation [Pellegrini et al., 2006], was found to be up-regulated, phosphorylation of SQ motifs in ATR was not detected. Notably, phosphorylation at S<sup>440</sup> in ATR was found to be up-regulated, suggesting that the activity of this kinase may also be modulated by phosphorylation at a site different from the SQ motif. Direct targets of ATR and ATM included proteins involved in the initial enzymatic processing step of DNA damage such as DNA strand breaks [i.e., Nbs1, Rad50, and H2AX], signaling mediators [i.e., MDC1, 53BP1], repair factors [i.e., BRCA1, BARD1, FANCD2], and checkpoint activators [i.e., CHK1] [Bartek and Lukas, 2007]. Interestingly, we identified multiple regulated phosphorylation sites on chromatin remodeling proteins [i.e., SMARCAD1, Chd1, Ino80, Rsf1, and HMGA1], E3 ubiquitin ligases [i.e., Np95, Ube3a, Huwe1, Rnf2, UBR7, Mdm2, TRIM33, and RNF19A], and a SUMO-protein ligase [i.e., RanBP2]. Moreover, proteins known to bind cisplatin-DNA adducts such as the high-mobility group proteins HMGA1 and HMGA2 [Todd and Lippard, 2009], revealed altered phosphorylation site abundance after treatment. The phosphorylation of the acidic C-terminal tail of HMGA2 has been associated with reduced DNA binding activity [Sgarra et al., 2009]. Phosphorylation sites S<sup>100</sup>, S<sup>101</sup>, and S<sup>104</sup> on the




**Figure 2.** [A] Phosphopeptide ratio plot. Red dots indicate phosphopeptides that were found more than 2-fold up- or down-regulated after cisplatin treatment; green dots indicate phosphopeptides that showed 1.5 to 2 fold up- and down-regulation after cisplatin treatment; blue dots indicate phosphopeptides that were not affected by cisplatin treatment. The y-axis represents signal intensity of the ions and it is related to the power [~amplitude squared] of the signal sine wave. [B] Top 50 up-regulated phosphopeptides. [C] Top 50 Down-regulated phosphopeptides. [D] MetaCore network analysis of proteins containing more than 1.5-fold up-regulated phosphorylation sites after cisplatin treatment. [E] MetaCore network analysis of proteins containing more than 1.5-fold down-regulated phosphorylation sites after cisplatin treatment. [F] MetaCore network analysis of proteins containing more than 2-fold up-regulated phosphorylation sites after cisplatin treatment. [G] MetaCore network analysis of proteins containing more than 2-fold down-regulated phosphorylation sites after cisplatin treatment.

acidic C-terminal tail and S<sup>44</sup> outside that domain of HMGA2 were found down-regulated after cisplatin treatment, suggesting an increased DNA binding to cisplatin-modified DNA. In contrast, we observed an enhanced phosphorylation of the S<sup>102</sup> and S<sup>103</sup> sites on the acidic C-terminal tail of HMGA1 after cisplatin treatment and, moreover, the phospho-S<sup>9</sup> [SQ motif] was present in the top ten cisplatin up-regulated phosphorylation sites.

### Kinase domain loop phosphorylation sites changes by cisplatin stress response

Based on consensus sequence, about half of the more than two-fold up-regulated phosphorylation sites were no canonical substrates of ATM or ATR, revealing substantial involvement of other kinases in the genotoxic stress response. The activity of many kinases is modulated by phosphorylation of the kinase domain loop located between the conserved amino acid sequence motifs DFG and APE [Nolen et al., 2004]. This domain plays a crucial role in substrate recognition. Phosphorylation of residues in this segment is frequently required for the correct alignment between the substrate and the catalytic site of the kinases [Johnson et al., 1996] and phosphorylation status of the activation loop can therefore be used as a proxy for kinase activity. Eleven kinases mainly belonging to the MAPK family were identified to be phosphorylated in the activation loop after cisplatin treatment [figure 4A]. Plk1, a kinases that play essential roles in the regulation of mitosis by coordinating spindle assembly and dynamics was found to be specifically dephosphorylated in its activation loops after cisplatin treatment. We tested the biological relevance of 11 of the regulated kinases for cisplatin induced toxicity by siRNA mediated knockdown and demonstrated a novel protective role for 3 of them [CDK7, Plk1, and KPCD1] [figure 4B]. In order to test the off-target effects, four individual siRNA were used to knockdown CDK7, Plk1, and KPCD1 respectively and the extent of knockdown was tested by western-blot [supplementary




**Figure 3.** [A] Consensus sequence for ATM, ATR, and DNA-PK substrates among the more than 2-fold up-regulated phosphorylation sites. [B] Consensus sequence for different kinases among up-regulated, down-regulated, and unmodified phosphorylation sites.

figure 4). We note here, that a significant reduction in cell survival was detected for the PLK1 knockdown in the absence of cisplatin treatment, indicating a critical role of this kinase in normal cell growth [supplementary figure 4] [Tyagi et al., 2010].

### Effects on mitosis

Analysis of kinase motifs among the phosphorylation sites showed a significant enrichment of CDK, ERK, and Aurora kinase substrates among the down-regulated phosphorylation sites



**Figure 4.** [A] Analysis of the kinase domain loop located between the conserved sequence DFG and APE. [B] The cellular sensitivity for cisplatin after siRNA knockdown was determined by an Adenosine TriPhosphate [ATP] monitoring system. Knock down of CDK7, PLK1, or KPCD1 kinases significantly reduced cell survival after cisplatin treatment [Student's *t* test]. siGFP [control 1] and siLAMIN C/A [control 2] were used as negative controls [two independent experiments]. [C] Effects of cisplatin on cytoskeleton structure. mES cells were exposed for 4 and 8 hours to cisplatin [5 $\mu$ M] treatment and stained with DY554-phalloidin and DAPI [nuclei]. The arrows indicate microspikes.

[figure 3B]. In response to persistent genotoxic stress, ATM and ATR and the subsequent Chk1/Chk2 signaling cascade prevent activation of Cdk1/CyclinB, thereby blocking entry into mitosis [Bartek and Lukas, 2007]. The depletion of mitotic cells evidenced by FACS analysis [figure 1C] is consistent with the activity of these cell-cycle kinases as indicated by the phosphoproteomics dataset. Following DNA damage, two mitosis-specific kinases, Cdk1 and Plk1, are inactivated by inhibitory phosphorylation [T<sup>14</sup> and Y<sup>15</sup>] [O'Farrell, 2001] and dephosphorylation [T<sup>210</sup>] [Tsvetkov and Stern, 2005] events, respectively. T<sup>14</sup> and Y<sup>15</sup> phosphorylation of Cdk1 and the dephosphorylation of the activation loop T<sup>210</sup> of Plk1 were evident in our data [supplementary table 1]. Several Plk1 targets involved in mitosis have been identified [Nigg, 2001], including FoxM1; this protein was found to be dephosphorylated after cisplatin treatment [supplementary table 1]. The FoxM1 protein is an important transcription factor involved in the regulation of mitotic entry [Laoukili et al., 2005; Wang et al., 2005] and phosphorylation of FoxM1 by Plk1 and Cdk1 regulates the transcription network essential for mitotic progression [Fu et al., 2008]. Remarkably, a wide range of proteins related to mitotic events were found to be dephosphorylated, i.e., KNSL1, nucleolin, histone H1, and the anaphase-promoting complex [APC]. APC is a multisubunit protein complex with E3 ubiquitin ligase activity essential for the proteolysis process, a key mechanism that drives the events of mitosis. APC1, APC2, Cdc20, Cdh1, and Cdc23 subunits of anaphase-promoting complex were found down-phosphorylated and very likely this alteration may facilitate the binding of Emi1, an inhibitor of APC [Torres et al., 2010].

### Effects on cytoskeleton

Cellular movement is orchestrated by microtubules and actin cytoskeleton and is controlled by the activity of Rho GTPases [Waterman-Storer and Salmon, 1999]. Prominent Rho GTPase family members are Rac1 and Cdc42, which induce the formation of extensions [lamellipodia] and stimulate actin polymerization at the leading edge of the cell together with the formation of new adhesion sites to the matrix [Ridley, 2001]. Cytoskeleton processes and, in particular, Rac-1 [P<10e-5] and Cdc42 [P<10e-4] pathways were found affected by genotoxic stress [supplementary figure 3]. Proteins associated with RAC-1 and Cdc42 pathways i.e., ABR, ECT2, DBL, RacGAP1, p200RhoGAP, ARCGAP22, and ARHGAP12, were found to be dephosphorylated on proline-directed serine/threonine sites [potential CDK or MAPK substrates] or sites that are targeted by casein kinases [in an acidic amino acid context]. To study the effect of cisplatin on cytoskeleton structure, we monitored the actin organization in mES cells after treatment [figure 4C]. Cytoskeleton remodeling and specific microspike formation were clearly visible in cells treated with cisplatin, confirming the results of the pathway analysis obtained from the phosphoproteome.

### Proteome and transcriptome


Non-phosphorylated peptides were analyzed to rule out that changes in overall protein levels might be responsible for the observed changes in phosphorylation site levels. Quantitative profiles were obtained for 4,349 proteins [figure 5A] out of a total of 5,917 proteins [supplementary table 2] based on the quantification of 16,305 non-phosphorylated but unique peptides [supplementary table 3]. The abundance of most proteins that contained

up- or down-regulated phosphorylation sites did not change significantly during cisplatin treatment, indicating that the majority of observed phosphorylation changes was not due to alterations in protein quantity (figure 5C-D-E). Interestingly, cellular levels of 455 proteins were found to be altered when proteomics data analysis was performed with a statistical rigor of  $P < 0.05$ . Network analysis identified cytoskeleton remodeling as one of the most prominent affected pathways. In particular, the NOTCH signaling pathway was statistically found to be significantly affected (supplementary figure 3). Metacore analysis shows an enrichment of p53 target genes ie 49 out of 455 proteins, double the expected frequency ( $P < 10e-6$ ), suggesting a p53-dependent response in line with previous studies [Kruse et al., 2007]. We examined how the proteome correlates to the mES transcriptome previously generated under identical conditions of cell growth and cisplatin exposure [Kruse et al., 2007]. Of a total of 3,616 Entrez gene ID shared among the gene expression and protein data sets, 386 proteins and 56 mRNAs transcripts were found to be significantly affected by cisplatin treatment ( $p < 0.05$ ), with surprisingly only 5 gene IDs being in common (supplementary table 5). A selected group of genes was examined by RT-PCR and western-blot analysis to quantify gene expression and protein levels in mES cells after cisplatin treatment. Indeed significant changes in protein levels were found for Cdh1, p53, Centrin2, Mark2 by immunoblotting whereas the corresponding mRNA transcripts were not affected after cisplatin (supplementary figure 5). Together, these data indicate that alterations in protein and transcript quantities do not correlate well at the individual gene level after cisplatin treatment. In contrast, pathway analysis based on transcriptomics, proteomics and phosphoproteomics data revealed a large overlap in affected processes (figure 6). Cell cycle was the most prominent pathway affected at the transcriptome and phosphoproteome level whereas DNA repair pathways were only significantly affected at phosphoproteome level. In contrast, changes at the overall protein level primarily involved processes associated with cytoskeleton regulation.

## DISCUSSION

Cisplatin is a widely used anticancer drug and, therefore, understanding of the molecular changes that underlie the biological consequences of treatment with this drug is of critical importance. Protein phosphorylation is one of the most prominent post-translational modifications that are triggered by cisplatin treatment and therefore, global phosphoproteome analysis is an excellently suited approach to identify molecular components and cellular pathways affected by cisplatin.

Inhibition of transcription and replication by cisplatin induced DNA lesions and subsequently the generation of DNA strand breaks activates the ATR and ATM kinases as well as p38MAPK/MK2 pathway [Bartek and Lukas, 2007; Reinhardt et al., 2007a; Reinhardt and Yaffe, 2009]. Consistently, we found up-regulation of S<sup>1987</sup> phosphorylation in ATM that is required for its activation [Pellegrini et al., 2006]. Up-regulation of ATR phosphorylation was observed at S<sup>440</sup>, a site that lacks the SQ motif and likely represents the site targeted by the NEK6 kinase. This kinase belongs to a large family of Ser/Thr kinases that have critical roles in coordinating microtubule dynamics during mitotic progression [Quarmby



**Figure 5.** [A] Unmodified peptide ratio plot. Red dots, significantly [ $p < 0.001$ ] regulated peptides after cisplatin treatment; green dots, significantly [ $p < 0.05$ ] regulated peptides after cisplatin treatment; blue dots, unmodified peptides after cisplatin treatment. The y-axis represents signal intensity of the ions and it is related to the power [ $\sim$ amplitude squared] of the signal sine wave. [B] MetaCore networks analysis of significantly affected proteins [ $p < 0.05$ ] after cisplatin addition. [C] Abundance distributions of all proteins and proteins containing up-regulated phosphorylation sites [ $>1.5$ -fold] [D] Abundance distributions of all proteins and proteins containing down-regulated phosphorylation sites [ $>1.5$ -fold]. [E] Abundance distributions of all proteins and proteins containing unmodified phosphorylation sites.




Figure 6: Comparison of significantly affected pathways [MetaCore network analysis] by cisplatin at the transcriptomic [mRNAs transcripts  $p < 0.05$ ], proteomic [proteins  $p < 0.05$ ] and phosphoproteomic level [phosphoprotein  $p < 0.05$ ].

and Mahjoub, 2005). This phosphorylation site has not been previously mapped and might represent a novel site involved in ATR activation. The top 50 up-regulated phosphorylation sites include a significant number of direct ATR and ATM targets related to DDR; most notably proteins involved in the processing step of double strand breaks (DSB), DNA damage signaling, stalled replication/transcription forks, checkpoint activation and chromatin remodeling proteins. In addition, E3 ubiquitin and SUMO-protein ligases were observed to be regulated by phosphorylation events highlighting the cross-talk between phosphorylation and other post-translational modifications in response to genotoxic stress [Bennetzen et al., 2010]. In contrast to the large-scale proteomic analysis of SQ specific phosphorylation sites in response to DNA damage induced by IR and UV [Matsuoka et al., 2007; Stokes et al., 2007], our global phosphoproteomics strategy allowed identification of putative ATM/ATR dependent and independent phosphorylation events. Indeed, DNA repair proteins such as BRCA1, Rad50, p53BP1, FANCI, and BARD-1 were found to contain up-regulated phosphorylation sites unrelated to ATM and ATR activity. As these data are not based on direct experimental evidence, we cannot exclude that ATM/ATR may also phosphorylate at non-consensus sites. Moreover, 44 proteins [mostly involved in DNA repair and including BRCA1 and Iro80, supplementary figure 2] underwent differential phosphorylation of adjacent sites [2-5 amino acids]. Differential phosphorylation might serve to create a molecular switching mechanism [Bennetzen et al., 2010] by a tightly controlled activity of several kinases and phosphatases. Different types of post-translational modifications controlled by such a mechanism might dynamically regulate the DDR for example the assembly and disassembly of factors at sites of damage [Bartek and Lukas, 2007].

Several of the HMG domain proteins recognize cisplatin adducts and display a selective affinity for clinically effective platinum drugs [Kartalou and Essigmann, 2001]. HMGA proteins are expressed at a high levels during embryonic development, whereas they are barely detectable in differentiated or non-proliferating cells; noteworthy, these proteins are highly re-expressed following neoplastic transformation [Sgarra et al., 2004]. HMGA1 and HMGA2 were found to be differentially phospho-regulated after cisplatin treatment. To our knowledge, these are the first *in vivo* data showing a discrepancy in phosphorylation state between HMGA1 and HMGA2 in response to genotoxic stress. The finding of differential phosphorylation profiles within the HMGA family after cisplatin treatment might offer potential targets for an improved cisplatin cancer therapy, considering that these proteins are overexpressed in cancers of different origins.

The outcome of an independent replicate experiment with same ES cells demonstrated the high reproducibility of the Cisplatin induced protein phosphorylation. The results also showed that ATM and ATR consensus sequences were significantly over-represented among hyper-phosphorylated peptides [supplementary figure 6D]. The phosphopeptide ratio correlation between the two replicates is 0.61 [Pearson correlation coefficient, R, supplementary figure 6A] based on 7,275 unique phosphopeptide identified in both experiments [supplementary table 7]. These results are close to those achieved in a recent study using a similar experimental approach [Rigbolt et al., 2011]. A much higher correlation [R=0.88] was found when the analysis was limited to putative ATM/ATR

substrate peptide ratios [supplementary figure 6A-B-E]. Importantly, network analysis identified DDR and cytoskeleton regulation as affected cisplatin processes in both experiments. Together these results demonstrate the reproducibility and general validity of our findings [supplementary figure 6F-G].

Our results indicate that the cellular response to genotoxic stress involves a large variety of protein kinases and phosphatases. Indeed, 11 kinases were identified to be regulated at phosphorylation sites-in the activation loop after cisplatin treatment (figure 4A). Most of those regulated belong to the MAPK family, but kinases not related to the MAPK family i.e Plk1 essential in the regulation of mitosis, was found to be dephosphorylated as well. Mitogen-activated protein kinases (MAPKs) are critical components of the signaling network activated by genotoxic stress and critical in deciding cell fate in response to cisplatin [Brozovic and Osmak, 2007]. Particularly, in the absence of p53, cells depend on p38MAPK/MK2 for cell-cycle arrest and survival after cisplatin [Reinhardt et al., 2007b]. Here we show that the kinase domain of MK14 [p38 $\alpha$ ] is activated by specific phosphorylation of the activation loop TXY motif after cisplatin addition.

Knock-down of CDK7 significantly increased cell toxicity after cisplatin treatment. The cyclin-dependent protein kinase CDK7 forms a trimeric complex with cyclin H and MAT1 and is both a Cdk-activating kinase [CAK] [Drapkin et al., 1996;Reardon et al., 1996] and an essential component of the transcription factor TFIIH, involved in transcription initiation and nucleotide excision repair [Scrace et al., 2008]. In addition, knock-down of Plk1, and KPCD1 also increased cisplatin mediated cytotoxicity (figure 4B). KPCD1 is a member of the protein kinase C [PKC] family involved in extracellular receptor-mediated signal transduction pathways [Johannes et al., 1994]. The mitosis-specific kinase Plk1 has been shown to play an essential role in the regulation of mitotic progression, including mitotic entry, spindle formation, chromosome segregation and cytokinesis; moreover, it has been found to be over-expressed in different types of tumor [Takai et al., 2005]. Inhibition of Plk1 is an efficient way to establish an irreversible G2 arrest after DNA damage induction in specific cancers with non-functional p53. In these cells typical G1 arrest is lost in response to DNA damage and cells display a stronger dependency on the G2 DNA damage checkpoint for protection against genotoxic insults [van Vugt et al., 2005] Our data suggest that the cellular response to inactivate PKL1 is directed towards prevention of mitotic entry in favor of apoptosis process [Macurek et al., 2008], that is in according to transcriptomics and phosphoproteomics analysis. Currently, several Plk inhibitors are in phase I or II clinical studies [Mross et al., 2008;Jimeno et al., 2010;Degenhardt and Lampkin, 2010], and in cancers with non-functional p53, Plk1 inhibition serves as a potent adjuvant therapy when combined with a DNA-damaging regimen such as cisplatin [Tyagi et al., 2010]. Together, our results clearly indicate that dissection of the cellular responses induced by cisplatin using phosphoproteome analysis in concert with functional genomics allows unraveling of targets and pathways that enhance the cytotoxic effects of cisplatin.

Proteins that were identified to be differentially phosphorylated upon cisplatin treatment also belonged to biological processes and structures not classified as or related to core DDR processes. In fact, unanticipated processes associated with cytoskeleton events were

identified by network analysis of proteins containing down-regulated phosphorylation sites and, in particular, Rac-1 and Cdc42 pathways were found affected by cisplatin. The actin component of the cytoskeleton is dynamically implicated in a variety of cell functions, including regulation of cell shape, adhesion, and motility and recent studies underline mechanisms of cisplatin mediated inhibition on invasion and migration of human cancer cells [Ramer et al., 2007;Karam et al., 2010;Paduch et al., 2009]. Cytoskeleton remodeling and specifically the induction of microspike formation was a clear effect of cisplatin treatment [figure 4C]. These results are in line with reports on microspike formation related to Cdc42 [Umikawa et al., 1999]. The regulation of phospho state of Rho GTPases [members of the Rac-1 and Cdc42 pathways] shown in this study, is consistent with the observed cisplatin mediated changes in cell morphology. Moreover, the link between cisplatin and Rac-1/ Cdc42 pathways is relevant in view of the fact that Cdc42 activity is associated with genome maintenance, cellular senescence regulation, and aging [Wang et al., 2007]. Although classically regarded as a nuclear DNA damaging agent, recent studies support a more promiscuous mode of action for cisplatin [Mandic et al., 2003;Emert-Sedlak et al., 2005;Safaei et al., 2005;Zeidan et al., 2008]. The current phosphoproteome analysis of kinases targets and their predicted activated substrates supports this finding by confirming previous data and providing evidence for the extra-nuclear targeting function that might play a role in cisplatin induced toxicity and in cell motility. A better understanding of the mechanisms of cisplatin action may provide novel therapeutic strategies that would block metastatic progression and reducing dissemination of tumor cells.

We tested the hypothesis whether changes in transcription profiling after cisplatin correlate with changes observed at the protein level. Consistent with previously published data [Olsen et al., 2010], we found no clear correlation between changes in the relative level of transcripts and corresponding proteins. This lack of correlation might be due to the fact that the cellular mechanisms involved in regulation of stability/degradation differ between mRNAs and their encoded proteins. This finding indicates that information derived from transcriptomic and proteomic analysis is different, but when merged generates a more comprehensive view of the signaling pathways affected by stressors. Interestingly, the phosphoproteomic analysis performed in our study led to the identification of most of the pathways that were affected at the transcriptome or proteome level. However, the impact of cisplatin on the DNA damage repair pathways was only manifested in the phosphoproteome analysis indicating that phosphorylation events are key to activate DNA repair pathways after genotoxic stress induced by cisplatin or in general to genotoxic agents that induce replication and transcription blocking lesions.

## MATERIAL AND METHODS

### Cell culture and cisplatin treatment

Cell culture and cisplatin treatment of wild type mES cells [B4418 and HM1 derived from C57/Bl6 and OLA/129 mouse genetic background, respectively] were essentially performed as previously described [Kruse et al., 2007]. Sub-confluent cultures of mES

cells were exposed to cisplatin [5  $\mu$ M], added directly to the culture medium. Cell cultures were incubated for different time periods after cisplatin administration [0.5, 2, 4, 8 h]. The Thermo Scientific Pierce Mouse Embryonic Stem Cell Kit, containing media and reagents specifically designed for analysis of protein by mass spectrometry [Thermo Scientific], was used for SILAC experiments.

### Phosphopeptides enrichment

Isolation and purification of phosphopeptides was performed according to already published procedures [Villen et al., 2007] with some modifications. Briefly, cells were lysed for 30 minutes in lysis buffer [8 M urea, 50 mM Tris pH 8.1, 75 mM NaCl, 1 mM MgCl<sub>2</sub>, 500 units benzonase and phosphatase inhibitors]. Samples were centrifuged for 15 minutes at 13,000 rpm and protein concentration was established by Qubit Protein Assay [Invitrogen]. 10 mg of proteins were first reduced with 2.5 mM DTT for 25 minutes at 60 °C and subsequently alkylated by incubation with 7 mM iodoacetamide for 15 minutes at room temperature, protected from light. The alkylation reaction was quenched by incubation with 2.5 mM DTT for 15 minutes at room temperature. Protein solution was diluted 8-fold with 25 mM Tris pH 8.1, 1 mM CaCl<sub>2</sub> and incubated for 15 hr at 37 °C with 100  $\mu$ g trypsin [Promega]. On the following day, the digestion reaction was stopped by addition of TFA to 0.4 % final concentration and the precipitate was removed by centrifugation for 5 minutes at 3,200 rpm. The supernatant was loaded on a Sep-Pak Vac 1 ml C18 cartridge [Waters], desalted by washing with 0.1 % acetic acid and eluted with 0.1 % acetic acid, 30 % acetonitrile. Eluted peptides were lyophilized and fractionated at 1 ml/min on a 9.4x200mm 5  $\mu$ m particle PolySULFOETHYL A SCX column [PolyLC] using a 70 minutes gradient from 0 to 75 mM KCl, 350 mM KCl for 38 minutes in 5 mM KH<sub>2</sub>P0<sub>4</sub> pH 2.65, 30% acetonitrile. Eighteen fractions with 6 ml eluate were collected, desalted on Sep-Pak Vac 1 ml C18 cartridge and lyophilized as mentioned before. In the desalting step, the last eight fractions were reduced to four fractions by loading two fractions on one cartridge giving a total of 14 fractions. After lyophilization, peptides were dissolved in solution A (300 mg/ml lactic acid, 80 % acetonitrile, 0.1 % TFA) and loaded on a titanium tip column [TopTip 1 -100  $\mu$ l, Glycen Corporation] prewashed with elution solution [15 mM NH<sub>4</sub>OH pH~10.5], equilibration solution [0.1 % TFA] and solution A. After sample loading, the tip column was washed with solution A and B [80 % acetonitrile (v/v), 0.1 % TFA (v/v)]. After washing, phosphopeptides were eluted with elution buffer and collected in an equal volume of 2 % TFA. For desalting, phosphopeptides were loaded on a Stage Tip C18 column [PROXEON] prewashed with methanol, solution B and 0.1 % TFA. The phosphopeptide solution was loaded on a Stage Tip, washed with 0.1 % TFA and eluted with solution B. Liquid was removed by lyophilization and stored at -80 °C till MS analysis.

### Mass spectrometric analysis.

#### LC-MS/MS

The dried phosphopeptide mixtures were acidified with 5% acetonitrile in 0.3% tri-fluoro acetic acid [TFA] to an end volume of 10  $\mu$ L, transferred to a 96-well plate and analyzed by online nanoflow liquid chromatography tandem mass spectrometry [LC-MS/MS] as

described previously [Olsen et al., 2009] with a few modifications. Briefly, all nanoLC-MS/MS-experiments were performed on an EASY-nLC™ system [Proxeon Biosystems, Odense, Denmark] connected to the LTQ-Orbitrap Velos [Thermo Electron, Bremen, Germany] through a nanoelectrospray ion source.

5  $\mu$ L of each phosphopeptide fraction was auto-sampled onto and directly separated in a 15 cm analytical column [75  $\mu$ m inner diameter] in-house packed with 3 $\mu$ m C18 beads [Reprosil-AQ Pur, Dr. Maisch] with a 90 min gradient from 5% to 30% acetonitrile in 0.5% acetic acid at a flow rate of 250 nL/min. The effluent from the HPLC was directly electrosprayed into the mass spectrometer by a platinum-based liquid-junction.

The LTQ-Orbitrap Velos instrument was operated in data-dependent mode to automatically switch between full scan MS and MS/MS acquisition. Instrument control was through Tune 2.6.0 and Xcalibur 2.1 Survey full scan MS spectra [from m/z 300 – 2000] were analyzed in the orbitrap detector with resolution R=30K at m/z 400 [after accumulation to a 'target value' of 1e6 in the linear ion trap]. The ten most intense peptide ions with charge states  $\geq 2$  were sequentially isolated to a target value of 5e4 and fragmented in octopole collision cell by Higher-energy Collisional Dissociation [HCD] with a normalized collision energy setting of 40%. The resulting fragments were detected in the Orbitrap system with resolution R=7,500. The ion selection threshold was 5,000 counts and the maximum allowed ion accumulation times were 500 ms for full scans and 250 ms for HCD.

Standard mass spectrometric conditions for all experiments were: spray voltage, 2.2 kV; no sheath and auxiliary gas flow; heated capillary temperature, 275°C; predictive automatic gain control [pAGC] enabled, and an S-lens RF level of 65%. For all full scan measurements with the Orbitrap detector a lock-mass ion from ambient air [m/z 445.120024] was used as an internal calibrant as described [Olsen et al., 2005]. A setting was also chosen where the additional SIM injection of the lock mass is deactivated, in order to save time.

## Raw MS data analysis

### *Peptide identification and quantitation by MASCOT and MaxQuant.*

Raw Orbitrap full-scan MS and ion trap MSA spectra were processed by MaxQuant as described [Cox et al., 2009; Cox and Mann, 2008]. In brief, all identified SILAC doublets were quantified, accurate precursor masses determined based on intensity-weighting precursor masses over the entire LC elution profiles and MS/MS spectra were merged into peak-list files [\*.msm]. Peptides and proteins were identified by Mascot [Matrix Science, London, UK] via automated database matching of all tandem mass spectra against an in-house curated concatenated target/decoy database; a forward and reversed version of the mouse International Protein Index [IPI] sequence database [version 3.37; 102,934 forward and reversed protein sequences from EBI [<http://www.ebi.ac.uk/IPI/>]] supplemented with common contaminants such as human keratins, bovine serum proteins and porcine trypsin. Tandem mass spectra were initially matched with a mass tolerance of 7 ppm on precursor masses and 0.02 Da for HCD fragment ions. Scoring was performed in MaxQuant as described previously. We required strict trypsin enzyme specificity and allowed for up to two missed cleavage sites. Cysteine carbamidomethylation [Cys +57.021464 Da] was

searched as a fixed modification, whereas N-acetylation of proteins [N-term +42.010565 Da], N-pyroglutamine [-17.026549 Da], oxidized methionine [+15.994915 Da] and phosphorylation of serine, threonine and tyrosine [Ser/Thr/Tyr +79.966331 Da] were searched as variable modifications.

### Peptide filtering and phosphorylation site localization

The resulting Mascot result files (\*.dat) were loaded into the MaxQuant software suite for further processing. In MaxQuant we fixed the estimated false discovery rate (FDR) of all peptide and protein identifications at 1%, by automatically filtering on peptide length, mass error precision estimates and Mascot score of all forward and reversed peptide identifications. Finally, to pinpoint the actual phosphorylated amino acid residue (s) within all identified phospho-peptide sequences in an unbiased manner, MaxQuant calculated the localization probabilities of all putative serine, threonine and tyrosine phosphorylation sites using the PTM score algorithm as described [Olsen et al., 2006].

### Phosphorylation Site Sequence Motifs Logo Plots

Only peptides with localization probabilities >0.75 were included in the downstream bioinformatic analysis [supplementary table 1S]. To identify enriched sequence motifs in the phosphorylation site dataset we made use of the already published kinase motifs [www.phosida.com] and an algorithm that extracts overrepresented motifs in a more unbiased manner [Soufi et al., 2009]. The algorithm was implemented in R [a programming language and software environment for statistical computing and graphics] using a Fisher's exact test to iteratively test for position specific over-representation of amino acid groups between two lists of prealigned sequences. The perl-package WebLogo was used internally in the algorithm to visualize the enriched sequence motifs as logo plots. Grouping of amino acids were done by the basis of related chemical properties [acidic, basic, aromatic, aliphatic, hydrophilic, amide, polar and cyclic] and alignment was done with a sequence window of +/- 6 amino acids surrounding the central phosphorylated serine, threonine or tyrosine residue. The iterative nature of the algorithm means it is successively reapplied on the result from an analysis - i.e. on both the subset of the lists which contains the most significantly overrepresented amino acid group and the subset that does not contain this amino acid group. All cisplatin regulated phosphorylation site sequences were compared to all unchanging sites and vice versa. We considered a motifs significant if it fulfilled our conservative cut-off of  $P < 0.001$  on the Bonferroni adjusted  $P$ -values.

### Network and pathways analysis

Network and pathway analysis were performed using MetaCore software [http://www.genego.com/metacore.php]. Proteins containing up-regulated phosphorylation sites [>1.5-fold and >2 fold] and down-regulated phosphorylation sites [>1.5-fold and >2 fold] were investigated. In most cases high-throughput experiments result in lists of genes or proteins of interest. The datasets usually contain anywhere between few dozens and few thousand genes/proteins. In MetaCore the significance is evaluated based on the size of the intersection between user's dataset and set of genes/proteins corresponding to a network

module/pathway in question, or rather the probability to randomly obtain intersection of certain size between user's set and a network/pathway follows hypergeometric distribution. The significance of the networks/pathways is evaluated for whether algorithm has succeeded in creating modules that have higher than random saturation with the genes of interest.

Networks are drawn from scratch by GeneGo annotators and manually curated and edited. There are about 110 cellular and molecular processes whose content is defined and annotated by GeneGo. Canonical pathway maps represent a set of about 650 signaling and metabolic maps covering human biology [signaling and metabolism] in a comprehensive way.

### Western blot analysis

Total cell extracts were obtained by direct lysis of the cells in Laemmli-SDS-sample buffer. Western blot analysis was performed as described previously [Fousteri et al., 2006] and protein bands were analyzed and visualized with the Odyssey® Infrared Imaging System [LI-COR] using secondary antibodies labeled with visible fluorophores. Antibodies employed were: mouse  $\alpha$ - $\gamma$ H2AX [Millipore], rabbit  $\alpha$ -H2B [Santa-Cruz], mouse  $\alpha$ -p53 [Santa Cruz Biotechnology DO-1], rabbit  $\alpha$ -CDK7 [cell signaling], rabbit  $\alpha$ -PLK1 [cell signaling], rabbit  $\alpha$ -KPCD1 [cell signaling], rabbit  $\alpha$ -centrin [cell signaling], rabbit  $\alpha$ -E-cadherin [cell signaling] and rabbit  $\alpha$ -mark2 [cell signaling].

### Flowcytometry analysis

For cell cycle analysis, samples were either treated with 5  $\mu$ M cisplatin for 0.5, 2, 4 or 8 hours or mock treated, after which EdU was added to a final concentration of 20  $\mu$ M. Cells were collected 45 minutes after addition of EdU label and stained for EdU and DNA using the Click-iT EdU flow cytometry assay kit [Invitrogen] according to the manufacturer's protocol.

To determine the mitotic index, samples were either treated with 5  $\mu$ M cisplatin for 0.5, 2, 4 or 8 hours, treated with 100 ng/ml nocodazole for 4 hours, or mock treated. Cells were collected and  $10^6$  cells were fixed with 70% ethanol. Cells were washed with PBS and incubated with Rb- $\alpha$ -Phospho [Ser10] Histone H3 antibody [Millipore]. After washing, samples were incubated with Go- $\alpha$ -Rb Alexafluor 488 antibody [Invitrogen]. After washing, cells were treated with RNase A [200  $\mu$ g/ml] and stained with propidium iodide [Biorad]. Cells were analyzed using a BD LSR II flowcytometer [BD Biosciences] and FACSDiva 5.0 software. Results were analyzed with WinMDI 2.8 software.

### Immunofluorescence staining

Cells were fixed in 4% formaldehyde in CSK buffer [100 mM NaCl, 300 mM sucrose, 10mM PIPES pH 6.8, 3mM MgCl<sub>2</sub>] and permeabilized by treatment with 0.5% Triton X-100 in PBS for 10 min. Actin was visualized by DY554-phalloidin [Sigma-Aldrich] and cells were counterstained with DAPI. Images were captured with a Zeiss Axioplan2 microscope equipped with a Zeiss Axiocam MRm camera using either a Plan-NEOFLUAR 40x/1.30 or 63x/1.25 objective.

### siRNA transfection

HM1 mES cells were transfected with 50nM final concentration of siRNA [Dharmacon], targeting for CHK2, CDK7, MAPK2, M3K2, MK14, MARK1, PDPK1, PLK1, KPC1, KPCD1

and SG269, as well as siGFP [control 1] and siLAMIN A/C [control 2], which were used as negative controls. Transfection was performed using Dharmafect 1 [Dharmacon] according to the manufacturer's instructions.  $10^3$  HM1 mES cells were transfected for 16h in  $\mu$ Clear<sup>®</sup> 96-well plates [Greiner], and the medium was refreshed every 24h for 48h.

#### Cell viability assay

At 64h post-siRNA transfection, HM1 mES cells were treated with either vehicle or  $10\mu\text{M}$  of cisplatin [Ebewe Pharma] for 24h. ATP Lite™ [Perkin Elmer] was then used according to the manufacturer's instructions for the assessment of cell viability. As an additional conformation that cisplatin was inducing apoptosis, the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-DL-Asp [OMe]-fluoromethylketone [zVAD-fmk] [Bachem, Bubendorf, Switzerland] was used to inhibit caspases and blocked cisplatin-induced apoptosis [supplementary figure 4A].

#### Gene expression analysis

The gene expression levels of Cdh1, p53, centrin2 and mark2 were quantified after exposure to  $5\mu\text{M}$  cisplatin for 4 hours using quantitative reverse transcriptase PCR [qRT-PCR]. The qRT-PCR was performed using the Applied 7900ht real-time PCR detection system [Applied Biosystems]. In three independent experiments the RNA was isolated from mES and purified using an RNeasy-kit [Qiagen]. qRT-PCR was performed using the FastStart Universal SYBR Green Master [Rox] [Roche] according to the manufacturer's instructions.

The following primers were used:

- Cdh1 forward: atcctcgccctgctgatt and Cdh1 reverse: accaccgttctcctccgta.
- p53 forward: atgcccatgctacagaggag and p53 reverse: agactggccttcttggctt.
- centrin2 forward: tgagactgggaaaatcattcaa and centrin2 reverse: caccatcctcatctcgatca
- mark2 forward: gaaagggacacggagcag and mark2 reverse: ccgcagcatgttgactt.
- mRNA expression values were normalized to the housekeeping genes: hypoxanthine-guanine phosphoribosyltransferase [HPRT].

## SUPPLEMENTARY TABLES

Supplementary tables will be available at: <http://mcb.asm.org/content/31/24/4964/suppl/DC1>

**Supplementary table 1** Phosphopeptides dataset

**Supplementary table 2** Proteins dataset

**Supplementary table 3** Peptides dataset

**Supplementary table 4** phosphopeptide-data set merged with the protein-data set

**Supplementary table 5** 386 proteins and 56 mRNAs transcripts significantly affected by cisplatin treatment [ $p < 0.05$ ]

**Supplementary table 6** Phosphopeptides dataset replicate experiment

**Supplementary table 7** phosphopeptide-data set merged between the two replicate phosphopeptide experiments


## REFERENCE LIST

1. Bartek,J. and J.Lukas. 2007. DNA damage checkpoints: from initiation to recovery or adaptation. *Curr. Opin. Cell Biol.* **19**: 238-245.
2. Bennetzen,M.V., D.H.Larsen, J.Bunkenborg, J.Bartek, J.Lukas, and J.S.Andersen. 2010. Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. *Mol. Cell Proteomics.* **9**: 1314-1323.
3. Bensimon,A., A.Schmidt, Y.Ziv, R.Elkon, S.Y.Wang, D.J.Chen, R.Aebersold, and Y.Shiloh. 2010. ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage. *Sci. Signal.* **3**: rs3.
4. Borst,P., S.Rottenberg, and J.Jonkers. 2008. How do real tumors become resistant to cisplatin? *Cell Cycle* **7**: 1353-1359.
5. Brozovic,A. and M.Osmak. 2007. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. *Cancer Lett.* **251**: 1-16.
6. Choudhary,C. and M.Mann. 2010. Decoding signalling networks by mass spectrometry-based proteomics. *Nat. Rev. Mol. Cell Biol.* **11**: 427-439.
7. Cox,J. and M.Mann. 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* **26**: 1367-1372.
8. Cox,J., I.Matic, M.Hilger, N.Nagaraj, M.Selbach, J.V.Olsen, and M.Mann. 2009. A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. *Nat. Protoc.* **4**: 698-705.
9. Degenhardt,Y. and T.Lampkin. 2010. Targeting Polo-like kinase in cancer therapy. *Clin. Cancer Res.* **16**: 384-389.
10. Drapkin,R., G.Le Roy, H.Cho, S.Akoulitchev, and D.Reinberg. 1996. Human cyclin-dependent kinase-activating kinase exists in three distinct complexes. *Proc. Natl. Acad. Sci. U. S. A* **93**: 6488-6493.
11. Dronkert,M.L. and R.Kanaar. 2001. Repair of DNA interstrand cross-links. *Mutat. Res.* **486**: 217-247.
12. Emert-Sedlak,L., S.Shangary, A.Rabinovitz, M.B.Miranda, S.M.Delach, and D.E.Johnson. 2005. Involvement of cathepsin D in chemotherapy-induced cytochrome c release, caspase activation, and cell death. *Mol. Cancer Ther.* **4**: 733-742.
13. Fousteri,M., W.Vermeulen, A.A.van Zeeland, and L.H.Mullenders. 2006. Cockayne syndrome A and B proteins differentially regulate recruitment of chromatin remodeling and repair factors to stalled RNA polymerase II in vivo. *Mol. Cell* **23**: 471-482.
14. Fu,Z., L.Malureanu, J.Huang, W.Wang, H.Li, J.M.van Deursen, D.J.Tindall, and J.Chen. 2008. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. *Nat. Cell Biol.* **10**: 1076-1082.
15. Furuta,T., T.Ueda, G.Aune, A.Sarasin, K.H.Kraemer, and Y.Pommier. 2002. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. *Cancer Res.* **62**: 4899-4902.
16. Hall,M.D., M.Okabe, D.W.Shen, X.J.Liang, and M.M.Gottesman. 2008. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. *Annu. Rev. Pharmacol. Toxicol.* **48**: 495-535.
17. Jackson,S.P. and J.Bartek. 2009. The DNA-damage response in human biology and disease. *Nature* **461**: 1071-1078.
18. Jimeno,A., B.Rubio-Viqueira, N.V.Rajeshkumar, A.Chan, A.Solomon, and M.Hidalgo. 2010. A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer. *Mol. Cancer Ther.* **9**: 311-318.
19. Johannes,F.J., J.Prestle, S.Eis, P.Oberhagemann, and K.Pfizenmaier. 1994. PKCu is a novel, atypical member of the protein kinase C family. *J. Biol. Chem.* **269**: 6140-6148.
20. Johnson,L.N., M.E.Noble, and D.J.Owen. 1996. Active and inactive protein kinases: structural basis for regulation. *Cell* **85**: 149-158.
21. Karam,A.K., C.Santiskulvong, M.Fekete, S.Zabih, C.Eng, and O.Dorigo. 2010. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. *Cytoskeleton [Haboken. ]* **67**: 535-544.
22. Kartalou,M. and J.M.Essigmann. 2001. Recognition of cisplatin adducts by cellular proteins. *Mutat. Res.* **478**: 1-21.
23. Keys,H.M., B.N.Bundy, F.B.Stehman, L.I.Muderspach, W.E.Chafe, C.L.Suggs, III,

- J.L.Walker, and D.Gersell. 1999. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *N. Engl. J. Med.* **340**: 1154-1161.
24. Kruse, J.J., J.P.Svensson, M.Huigsloot, M.Giphart-Gassler, W.G.Schoonen, J.E.Polman, H.G.Jean, W.B.van de, and H.Vrieling. 2007. A portrait of cisplatin-induced transcriptional changes in mouse embryonic stem cells reveals a dominant p53-like response. *Mutat. Res.* **617**: 58-70.
  25. Laoukili, J., M.R.Kooistra, A.Bras, J.Kauw, R.M.Kerkhoven, A.Morrison, H.Clevers, and R.H.Medema. 2005. FoxM1 is required for execution of the mitotic programme and chromosome stability. *Nat. Cell Biol.* **7**: 126-136.
  26. Loehrer, P.J. and L.H.Einhorn. 1984. Drugs five years later. Cisplatin. *Ann. Intern. Med.* **100**: 704-713.
  27. Macek, B., M.Mann, and J.V.Olsen. 2009. Global and site-specific quantitative phosphoproteomics: principles and applications. *Annu. Rev. Pharmacol. Toxicol.* **49**: 199-221.
  28. Macurek, L., A.Lindqvist, D.Lim, M.A.Lampson, R.Klompaker, R.Freire, C.Clouin, S.S.Taylor, M.B.Yaffe, and R.H.Medema. 2008. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. *Nature* **455**: 119-123.
  29. Mandic, A., J.Hansson, S.Linder, and M.C.Shoshan. 2003. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. *J. Biol. Chem.* **278**: 9100-9106.
  30. Matsuoka, S., B.A.Ballif, A.Smogorzewska, E.R.McDonald, III, K.E.Hurov, J.Luo, C.E.Bakalarski, Z.Zhao, N.Solimini, Y.Lerenthal, Y.Shiloh, S.P.Gygi, and S.J.Elledge. 2007. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science* **316**: 1160-1166.
  31. McWhinney, S.R., R.M.Goldberg, and H.L.McLeod. 2009. Platinum neurotoxicity pharmacogenetics. *Mol. Cancer Ther.* **8**: 10-16.
  32. Morris, M., P.J.Eifel, J.Lu, P.W.Grigsby, C.Levenback, R.E.Stevens, M.Rotman, D.M.Gershenson, and D.G.Mutch. 1999. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. *N. Engl. J. Med.* **340**: 1137-1143.
  33. Mross, K., A.Frost, S.Steinbild, S.Hedbom, J.Rentschler, R.Kaiser, N.Rouyrre, D.Trommeshauser, C.E.Hoesl, and G.Munzert. 2008. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. *J. Clin. Oncol.* **26**: 5511-5517.
  34. Nigg, E.A. 2001. Mitotic kinases as regulators of cell division and its checkpoints. *Nat. Rev. Mol. Cell Biol.* **2**: 21-32.
  35. Nolen, B., S.Taylor, and G.Ghosh. 2004. Regulation of protein kinases; controlling activity through activation segment conformation. *Mol. Cell* **15**: 661-675.
  36. O'Farrell, P.H. 2001. Triggering the all-or-nothing switch into mitosis. *Trends Cell Biol.* **11**: 512-519.
  37. Oliver, T.G., K.L.Mercer, L.C.Sayles, J.R.Burke, D.Mendus, K.S.Lovejoy, M.H.Cheng, A.Subramanian, D.Mu, S.Powers, D.Crowley, R.T.Bronson, C.A.Whittaker, A.Bhutkar, S.J.Lippard, T.Golub, J.Thomale, T.Jacks, and E.A.Sweet-Cordero. 2010. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. *Genes Dev.* **24**: 837-852.
  38. Olsen, J.V., B.Blagojev, F.Gnad, B.Macek, C.Kumar, P.Mortensen, and M.Mann. 2006. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. *Cell* **127**: 635-648.
  39. Olsen, J.V., L.M.de Godoy, G.Li, B.Macek, P.Mortensen, R.Pesch, A.Makarov, O.Lange, S.Horning, and M.Mann. 2005. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. *Mol. Cell Proteomics.* **4**: 2010-2021.
  40. Olsen, J.V., B.Macek, O.Lange, A.Makarov, S.Horning, and M.Mann. 2007. Higher-energy C-trap dissociation for peptide modification analysis. *Nat. Methods* **4**: 709-712.
  41. Olsen, J.V., J.C.Schwartz, J.Griep-Raming, M.L.Nielsen, E.Damoc, E.Denisov, O.Lange, P.Remes, D.Taylor, M.Splendore, E.R.Wouters, M.Senko, A.Makarov, M.Mann, and S.Horning. 2009. A dual pressure linear ion trap Orbitrap instrument with very high sequencing speed. *Mol. Cell Proteomics.* **8**: 2759-2769.
  42. Olsen, J.V., M.Vermeulen, A.Santamaria, C.Kumar, M.L.Miller, L.J.Jensen, F.Gnad, J.Cox, T.S.Jensen, E.A.Nigg, S.Brunak, and M.Mann. 2010. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. *Sci. Signal.* **3**: ra3.


43. Ong,S.E., B.Blagoev, I.Kratchmarova, D.B.Kristensen, H.Steen, A.Pandey, and M.Mann. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. *Mol. Cell Proteomics*. **1**: 376-386.
44. Paduch,R., W.Rzeski, and J.Klatka. 2009. The effect of cisplatin on human larynx carcinoma cell motility. *Folia Histochem. Cytobiol.* **47**: 75-79.
45. Pellegrini,M., A.Celeste, S.Difilippantonio, R.Guo, W.Wang, L.Feigenbaum, and A.Nussenzweig. 2006. Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo. *Nature* **443**: 222-225.
46. Quarmby,L.M. and M.R.Mahjoub. 2005. Caught Nek-ing: cilia and centrioles. *J. Cell Sci.* **118**: 5161-5169.
47. Ramer,R., K.Eichele, and B.Hinz. 2007. Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the anti-invasive action of cisplatin on human cancer cells. *Oncogene* **26**: 5822-5827.
48. Reardon,J.T., H.Ge, E.Gibbs, A.Sancar, J.Hurwitz, and Z.Q.Pan. 1996. Isolation and characterization of two human transcription factor IIH (TFIIH)-related complexes: ERCC2/CAK and TFIIH. *Proc. Natl. Acad. Sci. U. S. A* **93**: 6482-6487.
49. Reinhardt,H.C., A.S.Aslanian, J.A.Lees, and M.B.Yaffe. 2007a. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. *Cancer Cell* **11**: 175-189.
50. Reinhardt,H.C., A.S.Aslanian, J.A.Lees, and M.B.Yaffe. 2007b. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. *Cancer Cell* **11**: 175-189.
51. Reinhardt,H.C. and M.B.Yaffe. 2009. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. *Curr. Opin. Cell Biol.* **21**: 245-255.
52. Ridley,A.J. 2001. Rho GTPases and cell migration. *J. Cell Sci.* **114**: 2713-2722.
53. Rigbolt,K.T., T.A.Prokhorova, V.Akimov, J.Henningsen, P.T.Johansen, I.Kratchmarova, M.Kassem, M.Mann, J.V.Olsen, and B.Blagoev. 2011. System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. *Sci. Signal.* **4**: rs3.
54. Safaei,R. and S.B.Howell. 2005. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. *Crit Rev. Oncol. Hematol.* **53**: 13-23.
55. Safaei,R., K.Katano, B.J.Larson, G.Samimi, A.K.Holzer, W.Naerdemann, M.Tomioka, M.Goodman, and S.B.Howell. 2005. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. *Clin. Cancer Res.* **11**: 756-767.
56. Scrace,S.F., P.Kierstan, J.Borgognoni, L.Z.Wang, S.Denny, J.Wayne, C.Bentley, A.D.Cansfield, P.S.Jackson, A.M.Lockie, N.J.Curtin, D.R.Newell, D.S.Williamson, and J.D.Moore. 2008. Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. *Cell Cycle* **7**: 3898-3907.
57. Sgarra,R., E.Maurizio, S.Zammitti, S.A.Lo, V.Giancotti, and G.Manfioletti. 2009. Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. *J. Proteome. Res.* **8**: 2978-2989.
58. Sgarra,R., A.Rustighi, M.A.Tessari, J.Di Bernardo, S.Altamura, A.Fusco, G.Manfioletti, and V.Giancotti. 2004. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. *FEBS Lett.* **574**: 1-8.
59. Soufi,B., C.D.Kelstrup, G.Stoehr, F.Frohlich, T.C.Walther, and J.V.Olsen. 2009. Global analysis of the yeast osmotic stress response by quantitative proteomics. *Mol. Biosyst.* **5**: 1337-1346.
60. Stokes,M.P., J.Rush, J.MacNeill, J.M.Ren, K.Sprott, J.Nardone, V.Yang, S.A.Beausoleil, S.P.Gygi, M.Livingstone, H.Zhang, R.D.Polakiewicz, and M.J.Comb. 2007. Profiling of UV-induced ATM/ATR signaling pathways. *Proc. Natl. Acad. Sci. U. S. A* **104**: 19855-19860.
61. Takai,N., R.Hamanaka, J.Yoshimatsu, and I.Miyakawa. 2005. Polo-like kinases (Plks) and cancer. *Oncogene* **24**: 287-291.
62. Tichy,E.D. and P.J.Stam Brook. 2008. DNA repair in murine embryonic stem cells and differentiated cells. *Exp. Cell Res.* **314**: 1929-1936.
63. Todd,R.C. and S.J.Lippard. 2009. Inhibition of transcription by platinum antitumor compounds. *Metallomics*. **1**: 280-291.

64. Torres, J.Z., K.H. Ban, and P.K. Jackson. 2010. A specific form of phosphoprotein phosphatase 2 regulates anaphase-promoting complex/cyclosome association with spindle poles. *Mol. Biol. Cell* **21**: 897-904.
65. Tsvetkov, L. and D.F. Stern. 2005. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage. *Cell Cycle* **4**: 166-171.
66. Tyagi, S., K. Bhui, R. Singh, M. Singh, S. Raisuddin, and Y. Shukla. 2010. Polo-like kinase 1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73alpha in p53 mutant human epidermoid squamous carcinoma cells. *Biochem. Pharmacol.* **80**: 1326-1334.
67. Umikawa, M., H. Obaishi, H. Nakanishi, K. Satoh-Horikawa, K. Takahashi, I. Hotta, Y. Matsuura, and Y. Takai. 1999. Association of frabin with the actin cytoskeleton is essential for microspike formation through activation of Cdc42 small G protein. *J. Biol. Chem.* **274**: 25197-25200.
68. van Vugt, M.A., A. Bras, and R.H. Medema. 2005. Restarting the cell cycle when the checkpoint comes to a halt. *Cancer Res.* **65**: 7037-7040.
69. Villen, J., S.A. Beausoleil, S.A. Gerber, and S.P. Gygi. 2007. Large-scale phosphorylation analysis of mouse liver. *Proc. Natl. Acad. Sci. U. S. A* **104**: 1488-1493.
70. Wang, D., R. Hara, G. Singh, A. Sancar, and S.J. Lippard. 2003. Nucleotide excision repair from site-specifically platinum-modified nucleosomes. *Biochemistry* **42**: 6747-6753.
71. Wang, D. and S.J. Lippard. 2005. Cellular processing of platinum anticancer drugs. *Nat. Rev. Drug Discov.* **4**: 307-320.
72. Wang, I.C., Y.J. Chen, D. Hughes, V. Petrovic, M.L. Major, H.J. Park, Y. Tan, T. Ackerson, and R.H. Costa. 2005. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF [Skp2-Cks1] ubiquitin ligase. *Mol. Cell Biol.* **25**: 10875-10894.
73. Wang, L., L. Yang, M. Debidda, D. Witte, and Y. Zhong. 2007. Cdc42 GTPase-activating protein deficiency promotes genomic instability and premature aging-like phenotypes. *Proc. Natl. Acad. Sci. U. S. A* **104**: 1248-1253.
74. Waterman-Storer, C.M. and E. Salmon. 1999. Positive feedback interactions between microtubule and actin dynamics during cell motility. *Curr. Opin. Cell Biol.* **11**: 61-67.
75. Welsh, C., R. Day, C. McGurk, J.R. Masters, R.D. Wood, and B. Koberle. 2004. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. *Int. J. Cancer* **110**: 352-361.
76. Zeidan, Y.H., R.W. Jenkins, and Y.A. Hannun. 2008. Remodeling of cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. *J. Cell Biol.* **181**: 335-350.



**FigureS1.** [A] FACS analysis of B4418 mES cells either mock or cisplatin [5  $\mu$ M] treated for 4 hours and labeled by EdU for 45 minutes. Cells positive for EdU incorporation are indicated by green dots. The DNA content was analyzed by propidium iodide staining. [B] FACS analysis of mES cells either mock or Nocodazole treated for 2 hours. Cells positive for Phospho [Ser10] Histone H3 are indicated by green dots.

**2A**




**B**

Gene Names	Phosphosite position	SILAC Ratio H/L
Brc1a	1422	11.01
Pctk2	180	10.15
Trk1	515	10.05
Rfc5	7	9.59
Isg118	165	9.46
Mdc1	176	7.88
Atgaf19	336	6.89
Uhrf1	169	6.67
Tip3bp1	305	6.86
Hmgat1	9	6.77
Raf1	528	6.19
Taf1c	763	5.88
Aca11	360	5.79
Kdm4b	453	5.58
Brc1a	1197	5.53
Chk1	317	5.52
Bard1	543	5.42
Smm2	375	5.39
Smm2	385	5.39
Ppm1g	201	5.38
Mcm6	13	5.08
Smtm	798	4.69
Impact	9	4.84
Hdac3	74	4.71
Cggbp1	164	4.50
Chfr1	1398	4.45
Ncapd2	598	4.28
Ncapd2	1300	4.26
Rad51c	365	4.15
Orc11	256	4.12
Orc11	255	4.12
Mk67	2185	4.11
Wdhd1	898	4.09
Ranbp3	283	4.05
Ranbp3	277	4.05
Pus7	40	3.98
Palb2	154	3.96
Nsm-ce1a	375	3.91
Pus1	103	3.90
Nbn	398	3.83
Rps6ka6	510	3.76
Ptsma1	247	3.75
Rad50	690	3.73
Ncl	425	3.66
Zmynd4	1065	3.64
Nbn	58	3.59
Numa1	270	3.58
Hp1bp3	144	3.57
Trks1bp1	1611	3.49
H2ax	140	3.39


**C**

Gene Names	Phosphosite position	SILAC Ratio H/L
Kcne4	69	0.01
Golg4	891	0.01
Klf5	91	0.03
Ba2c11	1051	0.06
Rbm20	1020	0.07
Afl1	784	0.07
Rbm33	531	0.09
Aoz2	167	0.11
Rad51ap1	256	0.12
MH5	178	0.14
Sptbn1	2186	0.15
Syl13	67	0.15
Treppc9	971	0.16
Tnobb	328	0.17
Tnobb	324	0.17
8030462H17Rik	147	0.17
4930564M22Rik	5	0.17
Pf5556	1176	0.18
Nbr1	701	0.19
Nbr1	700	0.19
Sic7a1	616	0.21
Kap1305	615	0.21
Rbm33	816	0.22
Parg	297	0.22
Nacc1	145	0.23
Kdm1	132	0.23
Ythd2	2	0.24
Map7d1	275	0.24
Uhrf	99	0.25
Map3k1ip1	7	0.25
Map3	99	0.27
Ei4ebp2	65	0.27
Nlcat4	264	0.28
Acm1	137	0.28
Fcm1	1626	0.28
OTTMUSG0000016543	70	0.29
Rod1	27	0.29
Ag2	210	0.29
Aled2	168	0.29
Acaca	1299	0.30
Acaca	1300	0.30
Nlcat4	120	0.31
Gapw1	996	0.31
Asx12	1254	0.31
Brd8	175	0.31
Ahgap11a	946	0.32
Nlcat4	217	0.33
Nlcat4	213	0.33
Esmb	207	0.33
Sic1a4	507	0.33


**D**




**E**



**F**



**G**



**FigureS2.** [A] Proteins containing both phosphorylated and dephosphorylated sites. [B] Process Networks analysis of proteins containing both phosphorylated and dephosphorylated sites [MetaCore software]. [C] protein-protein interaction map.

<b>A</b>	<b>Cell cycle and its regulation</b>	<b>up-regulated phospho-sites (&gt;1.5-fold)</b>		<b>up-regulated phospho-sites (&gt;2-fold)</b>	
		<b>Pathways</b>	<b>pValue</b>	<b>pValue</b>	<b>pValue</b>
	1 DNA damage ATM/ATR regulation of G1/S checkpoint		4.72 10 <sup>-18</sup>		2.989 10 <sup>-11</sup>
	2 DNA damage ATM / ATR regulation of G2 / M checkpoint		1.63 10 <sup>-12</sup>		1.765 10 <sup>-8</sup>

<b>B</b>	<b>DNA-damage response</b>	<b>pValue</b>	
		<b>pValue</b>	<b>pValue</b>
	1 DNA damage Role of Brca1 and Brca2 in DNA repair	1.49 10 <sup>-16</sup>	3.054 10 <sup>-15</sup>
	2 DNA damage Role of NFB1 in DNA damage response	1.84 10 <sup>-14</sup>	4.047 10 <sup>-15</sup>
	3 DNA damage DNA-damage-induced responses	7.88 10 <sup>-10</sup>	1.661 10 <sup>-9</sup>

<b>C</b>	<b>Apoptosis</b>	<b>pValue</b>	
		<b>pValue</b>	<b>pValue</b>
	1 Apoptosis and survival DNA-damage-induced apoptosis	1.23 10 <sup>-13</sup>	4.068 10 <sup>-10</sup>
	2 Apoptosis and survival p53-dependent apoptosis	1.64 10 <sup>-7</sup>	4.352 10 <sup>-5</sup>
	3 Transcription P53 signaling pathway	2.1 10 <sup>-5</sup>	2.976 10 <sup>-2</sup>


  

<b>D</b>	<b>Pathways</b>	<b>down-regulated phospho-sites (&gt;1.5-fold)</b>		<b>down-regulated phospho-sites (&gt;2-fold)</b>	
		<b>pValue</b>	<b>pValue</b>	<b>pValue</b>	<b>pValue</b>
	1 G-protein signaling regulation of RAC1 activity	4.26 10 <sup>-6</sup>		1.376 10 <sup>-2</sup>	
	2 Cell adhesion endothelial cell contacts by junctional mechanisms	7.42 10 <sup>-6</sup>		1.22 10 <sup>-1</sup>	
	3 Cell cycle role of APC in cell cycle regulation	2.76 10 <sup>-5</sup>		5.18 10 <sup>-4</sup>	
	4 Cell cycle initiation of mitosis	9.32 10 <sup>-5</sup>		1.178 10 <sup>-1</sup>	
	5 G-protein signaling regulation of CDC42 activity	3.78 10 <sup>-4</sup>		5.678 10 <sup>-4</sup>	


  

<b>E</b>	<b>Pathways</b>	<b>pValue</b>	
		<b>pValue</b>	<b>pValue</b>
	1 Development NOTCH signaling pathway	7.1 10 <sup>-5</sup>	
	2 Development NOTCH-induced EMT	7.3 10 <sup>-5</sup>	


FigureS3: Topscores of most statistically relevant [lowest p value] pathways obtained from phosphopeptides up-regulated more than 1.5 and 2-fold after cisplatin treatment. [A] Cell cycle and its regulation. [B] DNA-damage response. [C] Apoptosis. [D] Topscores of, most statistically relevant [lowest p value], pathways obtained from phosphopeptides down-regulated more than 1.5 and 2-fold after cisplatin treatment. [E] Most statistically relevant pathways among of proteins with altered expression [p<0.05] after cisplatin treatment.



**Figure S4.** [A] Cell viability in presence of cisplatin. siGFP [control 1] and siLAMIN C/A [control 2] were used as negative controls. Cell viability could be restored by addition of the pan-caspase inhibitor [Z-VAD]. [B] Cell viability in absence of cisplatin was investigated after siRNA knockdown. Luminescence is relative to control 1. [C] The protein level of CDK7, PLK1, and KPCD1 kinases was determined by western-blot to test the protein knockdown for four independent siRNAs. [D] Four independent siRNAs for CDK7, PLK1, and KPCD1 kinases were used to test the cellular sensitivity for cisplatin by an Adenosine TriPhosphate [ATP] monitoring system. siGFP [control] was used as negative controls [two independent experiments].



**FigureS5.** [A] Relative gene expression levels of Cdh1, p53, centrin2 and Mark2 measured by quantitative RT-PCR. mES cells were mock treated [control;black bars] or treated for 4 hours 5 $\mu$ M cisplatin [grey bars]. [three independent experiments] [B] Relative protein levels of Cdh1, p53, centrin2 and Mark2 measured by western-blot between control [black bars] and 4 hours after 5 $\mu$ M cisplatin [grey bars] in mES [three independent experiments].



**Figure S6.** [A] Phosphopeptide ratio plot between the two replicate phosphopeptide experiments. ATM/ATR substrate phosphopeptides are represented in red [B] Top 40 ATM/ATR substrates up-regulated phosphopeptides in the two replicates. [C] Number of phosphopeptides up-regulated [ $>2$ ], down regulated [ $<0.5$ ], up/unchanged [ $1.5 < \text{ratio} < 2$ ] and down/unchanged [ $0.5 < \text{ratio} < 0.66$ ] [second experiment]. [D] Consensus sequence for ATM/ATR kinases among up-regulated, down-regulated, and unmodified phosphorylation sites [second experiment]. [E] pS/T-Q motifs phosphopeptide ratio plot between the two replicate phosphopeptide experiments. [F] MetaCore network analysis of proteins containing more than 2-fold up-regulated phosphorylation sites after cisplatin treatment [second experiment]. [G] MetaCore network analysis of proteins containing more than 2-fold down-regulated phosphorylation sites after cisplatin treatment [second experiment].



